Consensus guideline for the management of patients with appendiceal tumors Part 1: Appendiceal tumors without peritoneal involvement
PSM Appendiceal Tumor Writing Group, ; PSM Appendiceal Tumor Consortium Group, ; Turaga, K. K.
Show abstract
BackgroundAppendiceal tumors comprise a heterogeneous group of tumors which may be localized or disseminate throughout the peritoneum. Limited high quality clinical data exists and many practices have been extrapolated from colorectal cancer without validation in appendiceal cohorts. Many controversies exist regarding their treatment, and practices vary widely between centers and care settings. A national consensus update of best management practices for appendiceal malignancies was performed to better standardize care. MethodsThe 2018 Chicago consensus guideline was updated via modified Delphi consensus, performed over two rounds using nationally circulated surveys. Supporting evidence was evaluated using rapid systematic reviews. Key systemic therapy concepts were summarized by content experts. ResultsMost supporting literature consists of observational studies, but increasingly high-quality studies are becoming available to drive management. Two consensus-based pathways were generated for localized appendiceal tumors, one for epithelial mucinous neoplasms and another for appendiceal adenocarcinoma. Of 138 participants responding in the first round, 133 (96%) engaged in the second round. Over 90% consensus was achieved for all pathway blocks. Key points include minimizing intervention invasiveness where permitted by pathologic classification and margin status, and determining what margin and pathologic findings are indications for consideration of cytoreduction with or without intraperitoneal chemotherapy. Surveillance and systemic therapy recommendations are also presented. ConclusionWith growing but still primarily observational evidence currently dictating care, these consensus recommendations provide expert guidance in the treatment of appendiceal tumors without peritoneal involvement.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumors treated by cytoreductive surgery: Study protocol of a prospective, multi-center, observational study 94%
- Head-to-head comparison of the RMI and ADNEX models to estimate the risk of ovarian malignancy: systematic review and meta-analysis of external validation studies 90%
- Reproducibility and transparency characteristics of oncology research evidence 89%
Similar papers in this journal
- COVID-19 Outcomes in Patients with Cancer: Findings from the University of California Health System Database 92%
- Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel 89%
- A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer 88%
Similar papers in this journal
- Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high grade serous carcinoma 92%
- Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case-control study 90%
- Spatial, Temporal, and Molecular Heterogeneity of ADC targets in High-Grade Serous Ovarian Carcinoma 89%
Similar papers in this journal
- ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer 92%
- Molecular subtyping improves prognostication of Stage 2 colorectal cancer 91%
- Feasibility of Administering Human Pancreatic Cancer Chemotherapy in a Spontaneous Pancreatic Cancer Mouse Model 89%
Similar papers in this journal
- Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers 90%
- Cell-Free Tumor DNA Dominant Clone Allele Frequency (DCAF) Is Associated With Poor Outcomes In Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy 89%
- Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.